Anika Therapeutics | ANIK - Interest Expense On Debt


Anika Therapeutics reported 183.47M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Abbott USD 297M 2M Sep/2026
Agenus USD 14.67M 1.35M Mar/2026
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Anika Therapeutics 183.47M 4.09M Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 20.41M 1.57M Sep/2026
Integra LifeSciences USD 22.96M 33K Sep/2026
Intrexon USD 2K 5K Jun/2024
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
MacroGenics USD 4.4M 493K Jun/2026
Merit Medical Systems USD 7.33M 4.78M Sep/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR 222M 65M Sep/2026
Smith & Nephew USD 69M 1000K Dec/2025
Stryker USD 47.25B 683M Sep/2026
Veracyte USD 2K 1000 Dec/2023
Xencor USD 4.11M 3.24M Sep/2026
Zimmer Biomet Holdings USD 23.54B 740.8M Sep/2026